.Charles Baum, M.D., Ph.D., who looked after Mirati Therapeutics' $ 5.8 billion sale to Bristol Myers Squibb in 2014, is taking the controls of young biotech Terremoto Biosciences.Baum's "considerable experience in medicine development, and tried and tested record ahead of time high-impact medicines, are going to be instrumental," outgoing chief executive officer Peter Thompson, M.D., said in a July 25 release. Thompson will retain his seat as board chairperson..Baum, a skilled physician-scientist, was the founder, head of state and CEO of oncology-focused Mirati. Prior to that, he assisted cultivate cancer medicines at Pfizer as well as Schering-Plough..
Charles Baum, M.D., Ph.D.(( Mirati)).Now, Baum will serve as chief executive officer at Terremoto, a business building little particles to target disease-causing proteins-- like those discovered in cancerous tumor tissues-- utilizing covalent connections. Existing therapies that make use of covalent bonds predominantly target the amino acid cysteine. Having said that, of the 20 amino acids that compose proteins, cysteine is the least common. Terremoto is rather targeting among the necessary amino acids, amino acid lysine, which is located in almost all healthy proteins.By targeting lysine and various other amino acids, Terremoto expects to manage formerly undruggable ailments and also create first-in-class medications..The biotech, located in South San Francisco, increased $75 million in series A financing in 2022. A little much more than a year eventually, the biotech more than multiplied that variety in a $175 million series B.